Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 15/20 | 0.54 |
| ▸ | RARG | P13631 | 15/20 | 0.54 |
| ▸ | RARA | P10276 | 14/20 | 0.54 |
| ▸ | RXRA | P19793 | 9/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.45 |
| ▸ | GMNN | O75496 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | THPO | P40225 | 1/20 | 0.45 |
| ▸ | MTOR | P42345 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9551739 | 0.81 | RARB (0.69) | RARBRARGRARARXRACYP26A1 | |
| SCHEMBL5846340 | 0.79 | RARB (0.77) | RARBRARGRARARXRARXRB | |
| SCHEMBL10549628 | 0.78 | RARG (0.57) | RARBRARGRARARXRARXRB | |
| SCHEMBL8902795 | 0.77 | RARB (0.59) | RARBRARGRARARXRAKDM4E | |
| SCHEMBL8902801 | 0.77 | RARB (0.59) | RARBRARGRARARXRAKDM4E | |
| SCHEMBL7265393 | 0.77 | RARG (0.63) | RARBRARGRARARXRA | |
| SCHEMBL8350702 | 0.72 | RARG (0.64) | RARBRARGRARARXRARXRB | |
| SCHEMBL6473276 | 0.71 | RXRA (0.60) | RARBRARGRARARXRACYP26A1 | |
| SCHEMBL6473274 | 0.71 | RXRA (0.60) | RARBRARGRARARXRACYP26A1 | |
| SCHEMBL24259975 | 0.71 | CYP26A1 (0.76) | RARBRARGRARARXRAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2392562-B1 | Structural carotenoid analogs for the inhibition and amelioration of disease | CARDAX PHARMA INC (US) | 2018-03-07 | — | — | EP | disclosed |
| EP-1532108-B1 | ASTAXANTHIN ESTERS FOR THE INHIBITION AND AMELIORATION OF DISEASE | CARDAX PHARMA INC (US) | 2016-06-29 | — | — | EP | disclosed |
| EP-2392562-A1 | Structural carotenoid analogs for the inhibition and amelioration of disease | Cardax Pharmaceuticals, Inc. (US) | 2011-12-07 | — | — | EP | disclosed |
| US-7723327-B2 | Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease | CARDAX PHARMACEUTICALS, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-7592449-B2 | Structural carotenoid analogs for the inhibition and amelioration of disease | CARDAX PHARMACEUTICALS, INC. (US) | 2009-09-22 | — | — | US | disclosed |
| US-7521584-B2 | Carotenoid analogs or derivatives for the inhibition and amelioration of disease | CARDAX PHARMACEUTICALS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-7345091-B2 | Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease | CARDAX PHARMACEUTICALS, INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-7145025-B2 | Structural carotenoid analogs for the inhibition and amelioration of disease | HAWAII BIOTECH, INC. (US) | 2006-12-05 | — | — | US | disclosed |
| US-20060229446-A1 | Structural carotenoid analogs for the inhibition and amelioration of disease | HAWAII BIOTECH, INC. | 2006-10-12 | — | — | US | disclosed |
| US-20050148517-A1 | Carotenoid ether analogs or derivatives for controlling connexin 43 expression | CARDAX PHARMACEUTICALS, INC. | 2005-07-07 | — | — | US | disclosed |
| US-20050090469-A1 | Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease | CARDAX PHARMA, INC. | 2005-04-28 | — | — | US | disclosed |
| US-20050075316-A1 | Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease | CARDAX PHARMA, INC. | 2005-04-07 | — | — | US | disclosed |
| US-20050075337-A1 | Pharmaceutical compositions including carotenoid analogs or derivatives for the inhabition and amelioration of disease | CARDAX PHARMACEUTICALS, INC. | 2005-04-07 | — | — | US | disclosed |
| US-20050059635-A1 | Carotenoid ester analogs or derivatives for controlling C-reactive protein levels | CARDAX PHARMACEUTICALS, INC. | 2005-03-17 | — | — | US | disclosed |
| US-20050059659-A1 | Carotenoid analogs or derivatives for controlling C-reactive protein levels | CARDAX PHARMACEUTICALS, INC. | 2005-03-17 | — | — | US | disclosed |
| US-20050009788-A1 | Carotenoid ester analogs or derivatives for controlling connexin 43 expression | CARDAX PHARMACEUTICALS, INC. | 2005-01-13 | — | — | US | disclosed |
| US-20050009758-A1 | Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease | CARDAX PHARMA, INC. | 2005-01-13 | — | — | US | disclosed |
| US-20050004235-A1 | Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease | CARDAX PHARMACEUTICALS, INC. | 2005-01-06 | — | — | US | disclosed |
| US-20040162329-A1 | Structural carotenoid analogs for the inhibition and amelioration of disease | CARDAX PHARMA, INC. | 2004-08-19 | — | — | US | disclosed |
| WO-2004011423-A2 | STRUCTURAL CAROTENOID ANALOGS FOR THE INHIBITION AND AMELIORATION OF DISEASE | HAWAII BIOTECH, INC. (US) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075337-A1 | Pharmaceutical compositions including carotenoid analogs or derivatives for the inhabition and amelioration of disease | CYP11B2, CYP11B1, NQO1 | RARB 1416/4885RARG 1149/4885RARA 1063/4885 |
| US-20050009788-A1 | Carotenoid ester analogs or derivatives for controlling connexin 43 expression | GJA1, GJB2, CRY1 | RARB 290/4885RARG 398/4885RARA 211/4885 |
| US-20050148517-A1 | Carotenoid ether analogs or derivatives for controlling connexin 43 expression | GJA1, GJB2, CRY1 | RARB 230/4885RARG 278/4885RARA 152/4885 |
| US-20060229446-A1 | Structural carotenoid analogs for the inhibition and amelioration of disease | HCCS, CASP12, BAD | RARB 783/4885RARG 710/4885RARA 488/4885 |
| US-20050059635-A1 | Carotenoid ester analogs or derivatives for controlling C-reactive protein levels | TTPA, PROC, RBP4 | RARB 992/4885RARG 1284/4885RARA 683/4885 |
| US-20050059659-A1 | Carotenoid analogs or derivatives for controlling C-reactive protein levels | RBP1, PROC, RBP4 | RARB 869/4885RARG 1043/4885RARA 480/4885 |
| US-20050090469-A1 | Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease | GYS2, HCCS, CPT1A | RARB 446/4885RARG 582/4885RARA 384/4885 |
| US-20050075316-A1 | Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease | CYP11B2, CYP11B1, PTGER1 | RARB 1521/4885RARG 1479/4885RARA 1201/4885 |
| US-20040162329-A1 | Structural carotenoid analogs for the inhibition and amelioration of disease | HCCS, CASP12, BAD | RARB 783/4885RARG 710/4885RARA 488/4885 |
| US-20050009758-A1 | Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease | NFE2L2, GPX4, CYP11B2 | RARB 679/4885RARG 604/4885RARA 404/4885 |
| US-20050004235-A1 | Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease | GYS2, HCCS, CPT1A | RARB 450/4885RARG 566/4885RARA 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.